NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Alaunos Therapeutics, Inc. (TCRT) Stock Analysis

Alaunos Therapeutics, Inc. (TCRT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

TCRT

$3.08

+$0.11 (+3.70%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TCRT with… →

TCRT Key Statistics

As of Oct 21, 2026
Trading
Open
$3.13
Previous Close
$2.97
Day's Range
2.82–3.33
52-Week Range
0.72–4.50
Volume
2.57M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.87
Valuation
Market Cap
$9.02M
P/E Ratio
unprofitable
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.58
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3,005.19
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.76
Financials (FY)
Revenue (FY)
$5.00K−50.00%
Net Income (FY)
−$4.18M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
2.93M
1-Year Return
+11.19%
Dividend and dates
Avg Volume
7.40M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, TCRT closed at $3.08, +11.19% over 1 year.

Alaunos Therapeutics, Inc. (TCRT) has a market capitalization of $9.02M.

In fiscal 2025, TCRT reported revenue of $5.00K.

TCRT Stock Return by Calendar Year

Alaunos Therapeutics, Inc. (TCRT) 10-year return: what $10,000 became

1 year
$10,000 $11,119
+11.19%
5 years
$10,000 $125
−98.75%
10 years
$10,000 $37
−99.63%

If you had invested $10,000 in Alaunos Therapeutics, Inc. (TCRT) 10 years ago, at the close on October 21, 2016, it would have been worth $37 at the close on October 21, 2026: −99.63% in total, −42.88% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−4.64%
2025+69.11%
2024−81.81%
2023−89.23%
2022−40.37%
2021−56.75%
2020−46.61%
2019+152.41%
2018−54.83%
2017−22.62%
2016 (partial year)+9.86%

As of October 21, 2026.

TCRT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$5.00K−$4.18M−83,520.0%
2024$10.00K−$4.68M−46,790.0%
2023$5.00K−$35.14M−702,800.0%
2022$2.92M−$37.73M−1,291.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$5.00K—−$4.23M−$4.18M−83,520.0%
2024$10.00K—−$4.81M−$4.68M−46,790.0%
2023$5.00K—−$28.49M−$35.14M−702,800.0%
2022$2.92M—−$35.24M−$37.73M−1,291.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 8 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Alaunos Therapeutics, Inc. (TCRT) is capitalised at $9.02M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 1.

The 52-week range on file runs from $0.72 to $4.50. TCRT last closed at $3.08 on October 21, 2026. That is +$0.11 (+3.70%) against the previous close. The latest close sits 327.78% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $5.00K. Against the prior fiscal year total of $10.00K, that is a change of −50.00%. The same year closed with a net loss of $4.18M. Earnings per share on a trailing basis come to −1.76.

Across the 4 fiscal years on file, revenue moves from $2.92M in 2022 to $5.00K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.58. Measured against sales, the shares trade at 3,005.19 times revenue. On price-to-sales that is 226 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The reported beta is −0.87. Annualized volatility over the trailing 10 years is 123.34%. The trailing one-year total return is +11.19%. Across 10 years the annualized return works out at −42.88%.

Growth & Income

The record shows no dividend for TCRT.

2026 is still running; the total return is −4.64% year to date. Across the complete calendar years on file, 2019 returned +152.41% and 2023 returned −89.23%. Of the 9 complete calendar years on file, 2 finished higher.

Peer Comparison

Alaunos Therapeutics, Inc. (TCRT) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Alaunos Therapeutics, Inc. TCRT $9.02M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Alaunos Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Alaunos Therapeutics, Inc.

Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida.

Visit website →